| 摘要 |
<p>The invention refers to the treatment of eosinophil-mediated diseases with paf antagonists and a procedure for determining their efficacy. According to the invention for treating a disease mediated by eosinophils an effective amount of at least one paf antagonist is administered to a subject requiring said treatment of allergy and inflammation including allergic, inflammatory, nephrotic and hepatic oedema formation, wherein the paf antagonist is a hydrophilic or non-hydrophilic triazolothienodiazepine or a homologue thereof, a ginkgolide, a ginkgolide mixture or a synthetic ginkgolide derivate, or an analogue of the paf or a mixture with/of these compounds. <IMAGE></p> |
